Edition:
United States

Stemline Therapeutics Inc (STML.OQ)

STML.OQ on NASDAQ Stock Exchange Capital Market

7.38USD
2:20pm EDT
Change (% chg)

$-0.07 (-0.94%)
Prev Close
$7.45
Open
$7.42
Day's High
$7.62
Day's Low
$7.33
Volume
4,019
Avg. Vol
28,066
52-wk High
$11.70
52-wk Low
$3.93

STML.OQ

Chart for STML.OQ

About

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the... (more)

Overall

Beta: 0.23
Market Cap(Mil.): $141.88
Shares Outstanding(Mil.): 19.04
Dividend: --
Yield (%): --

Financials

  STML.OQ Industry Sector
P/E (TTM): -- 41.55 39.69
EPS (TTM): -2.20 -- --
ROI: -39.61 -9.57 14.44
ROE: -39.80 -9.91 15.49

BRIEF-Stemline Therapeutics reports Q1 loss per share $0.51

* Stemline Therapeutics reports first quarter 2016 financial results

May 09 2016

Competitors

  Price Chg
Astellas Pharma Inc (4503.T) ¥1,722 +27.00
Eisai Co., Ltd (4523.T) ¥6,044 -9.00
Sumitomo Dainippon Pharma Co Ltd (4506.T) ¥1,926 +44.00
Pfizer Inc. (PFE.N) $36.89 +0.22
Novartis AG (NOVN.S) CHF80.30 0.00
Merck & Co., Inc. (MRK.N) $58.66 +0.23
Roche Holding Ltd. (ROG.S) CHF247.50 +2.00
Roche Holding Ltd. (RO.S) CHF249.60 +1.80
Sanofi SA (SASY.PA) €76.15 -0.14
GlaxoSmithKline plc (GSK.L) 1,688.00p -11.50

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : Pechala's Reports
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Ford Investor Services, Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.